相关实验视频

Updated: Sep 11, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

在复发性/耐药性多发性骨髓瘤中降级的Teclistamab剂量:捷克骨髓瘤组真实世界的证据分析分析

Martin Stork¹, Jakub Radocha², Jana Mihalyova^3,4

¹Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic. stork.martin@fnbrno.cz.

Annals of hematology

|August 18, 2025

概括

早期减少多发性骨髓瘤的双特异性抗体 - - teclistamab的剂量,维持了疗效和安全性. 这些真实数据支持个性化治疗计划,以提高复发性/耐药性多发性髓瘤患者的耐受性.

科学领域:

在瘤学瘤学.
血液学血液学血液学
免疫治疗是一种免疫疗法.

背景情况:

针对BCMA和CD3的双特异性抗体Teclistamab在复发性/耐火性多发性髓瘤 (RRMM) 中显示出有前途.
在现实环境中,尚未建立teclistamab的最佳剂量策略.

研究的目的:

在RRMM患者中评估teclistamab单一治疗的疗效和安全性,使用标准剂量与减少频率剂量.
探索早期剂量降级对治疗结果的影响.

主要方法:

对73名RRMM患者进行了回顾性多中心分析,这些患者接受了teclistamab治疗.
对每周服用剂量和减少频率服用剂量的患者之间的结局进行比较.
分析无进展生存期 (PFS),相对剂量强度和不良事件.

主要成果:

在每周 (9.1个月) 和非每周 (11.3个月) 剂量组 (p=0.141) 之间,中位数的PFS是可比的.
降低频率剂量具有显著较低的相对剂量强度 (60.5%对87.0%;p<0.001),但类似的感染率和严重不良事件.
较低的中性质减退发病率被观察到较少的剂量,没有增加的感染负担.

结论:

在现实实践中早期降低teclistamab剂量可以保持临床疗效.
这些发现支持个性化治疗计划,以平衡BCMA向治疗中的有效性和耐受性.

关键词:

免疫治疗是一种免疫疗法.多发性骨髓瘤是一种多发性骨髓瘤.现实世界的证据.机械师是没有的.

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...